Gene therapy of neuropathic pain after spinal cord injury

Irina V. Kalashnikova, Matthew A. Farmer, Jonghyuck Park, Lonnie D. Shea

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Neuropathic pain (NPP) following spinal cord injury (SCI) is caused by damage to or dysfunction of the nervous system. Despite years of research, this type of neurological disorder remains refractory to treatment and persists for decades. Moreover, many spinal cord injury victims suffer from life-threatening side effects of traditional pharmacologic treatments—including addiction to multiple prescription drugs—in an attempt to alleviate neuropathic pain. In recent years, considerable research bodies have been dedicated to the discovery and understanding of neuropathic pain mechanisms that gave impetus for advances in treatment. Gene therapy is designed for genetic improvement through the correction of altered (mutated) genes or site-specific modifications that target therapeutic treatment. This chapter presents an overview of the currently available gene therapy strategies against neuropathic pain induced by spinal cord injury.

Original languageEnglish
Title of host publicationSpinal Cord Injury Pain
Number of pages19
ISBN (Electronic)9780128186626
StatePublished - Jan 1 2022

Bibliographical note

Publisher Copyright:
© 2022 Elsevier Inc. All rights reserved.


  • Cellular vehicles
  • Gene therapy
  • Neuropathic pain
  • Nonviral vectors
  • Spinal cord injury
  • Viral vectors

ASJC Scopus subject areas

  • General Medicine
  • General Neuroscience


Dive into the research topics of 'Gene therapy of neuropathic pain after spinal cord injury'. Together they form a unique fingerprint.

Cite this